DUMITRASCU, Dan, Igor BAKULIN, Annalisa BERZIGOTTI, Marilia CRAVO, Laura GOMBOSOVA, Milan LUKAS, Anna PIETRZAK, Jose Maria REMES-TROCHE, Manuel ROMERO-GOMEZ, Mercedes Amieva BALMORI, Tiago Curdia GONCALVES, Lamine HAMZAOUI, Radovan JURICEK, Leticia MOREIRA, Katarzyna NEUBAUER, Teodora SURDEA-BLAGA, Igor N TIKHONOV, Jan TRNA, Gianluca IANIRO, Francesca Romana PONZIANI and Antonio GASBARRINI. Update on the Role of Rifaximin in Digestive Diseases. Journal of Gastrointestinal and Liver Diseases. CLUJ-NAPOCA: MEDICAL UNIV PRESS, 2023, vol. 32, No 1, p. 92-109. ISSN 1841-8724. Available from: https://dx.doi.org/10.15403/jgld-4871.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Update on the Role of Rifaximin in Digestive Diseases
Authors DUMITRASCU, Dan (guarantor), Igor BAKULIN, Annalisa BERZIGOTTI, Marilia CRAVO, Laura GOMBOSOVA, Milan LUKAS, Anna PIETRZAK, Jose Maria REMES-TROCHE, Manuel ROMERO-GOMEZ, Mercedes Amieva BALMORI, Tiago Curdia GONCALVES, Lamine HAMZAOUI, Radovan JURICEK, Leticia MOREIRA, Katarzyna NEUBAUER, Teodora SURDEA-BLAGA, Igor N TIKHONOV, Jan TRNA (203 Czech Republic, belonging to the institution), Gianluca IANIRO, Francesca Romana PONZIANI and Antonio GASBARRINI.
Edition Journal of Gastrointestinal and Liver Diseases, CLUJ-NAPOCA, MEDICAL UNIV PRESS, 2023, 1841-8724.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30219 Gastroenterology and hepatology
Country of publisher Romania
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.100 in 2022
RIV identification code RIV/00216224:14110/23:00131030
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.15403/jgld-4871
UT WoS 000972987600016
Keywords in English liver cirrhosis; hepatic encephalopathy; irritable bowel syndrome; diverticular disease; gut  microbiome; rifaximin-?; symptomatic uncomplicated diverticular disease
Tags 14110811, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 21/6/2023 13:32.
Abstract
Various environmental factors affecting the human microbiota may lead to gut microbial imbalance and to the development of pathologies. Alterations of gut microbiota have been firmly implicated in digestive diseases such as hepatic encephalopathy, irritable bowel syndrome and diverticular disease. However, while these three conditions may all be related to dysfunction of the gut-liver-brain axis, the precise pathophysiology appears to differ somewhat for each. Herein, current knowledge on the pathophysiology of hepatic encephalopathy, irritable bowel syndrome, and diverticular disease are reviewed, with a special focus on the gut microbiota modulation associated with these disorders during therapy with rifaximin. In general, the evidence for the efficacy of rifaximin in hepatic encephalopathy appears to be well consolidated, although it is less supported for irritable bowel syndrome and diverticular disease. We reviewed current clinical practice for the management of these clinical conditions and underlined the desirability of more real-world studies to fully understand the potential of rifaximin in these clinical situations and obtain even more precise indications for the use of the drug.
PrintDisplayed: 28/8/2024 00:09